AFTAB QADIR: Open Payments
NPI 1972674349 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,646 in 40 payments from 13 companies in 2025. Trend: 2023 $1,977 · 2024 $2,109 · 2025 $1,646
Food & beverage: $1,646
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $424 |
| Axsome Therapeutics, Inc. | 6 | $205 |
| Teva Pharmaceuticals USA, Inc. | 5 | $155 |
| Noven Therapeutics, LLC | 2 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $137 |
| Luye Pharma (USA) Ltd. | 1 | $125 |
| Alkermes, Inc. | 1 | $120 |
| ABBVIE INC. | 7 | $113 |
| Janssen Pharmaceuticals, Inc | 3 | $70 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
Products named: COBENFY, Auvelity, Xelstrym, AUSTEDO XR, CAPLYTA, ERZOFRI EXTENDED-RELEASE, LYBALVI, VRAYLAR.
Industry payments across FL — which companies pay providers there.
